ERRATUM

Erratum to: LPTM4B-35 is a novel prognostic factor for glioblastoma

Xiaoshu Dong¹ · Kaoru Tamura¹ · Daisuke Kobayashi² · Noboru Ando² · Kazutaka Sumita¹ · Taketoshi Maehara¹

Published online: 9 March 2017
© Springer Science+Business Media New York 2017

Erratum to: J Neurooncol DOI 10.1007/s11060-017-2369-0

The original article contains the following errors:

1. The first author's name was incorrect (Xiaoshu Dong); it is correct in this erratum (Xiaoshu Dong).
2. In Fig. 2, the survival curves of A and B were interchanged. In addition, the number of patients specified in the legend of Fig. 2 was incorrect. The number of patients with high LPTM4B-35 expression should have read 23 (instead of 22) and the number of patients with low LPTM4B-35 expression should have read 16 (instead of 17). The correct Fig. 2 and caption are printed below.
3. In the Table 1, the number of LPTM4B low patients should have read 16 (instead of 12).
4. In the Table 1, the number of LPTM4B high patients should have read 23 (instead of 27).
5. In the Supplementary Table 1, the number of gross total resections in grade IV patients should have read 12 (27.9%), instead of 21 (48.8%).

The online version of the original article can be found under doi:[10.1007/s11060-017-2369-0](https://doi.org/10.1007/s11060-017-2369-0).

✉ Kaoru Tamura
kaoru-tmd@umin.ac.jp

¹ Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

² Department of Pathology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

Fig. 2 Kaplan–Meier curves for progression-free survival and overall survival in 39 GBM patients according to LPTM4B-35 expression. **a** The median progression-free survival of GBM patients with high LPTM4B-35 expression ($n=23$) was 5.13 ± 4.72 months, significantly shorter than that of patients with low LPTM4B-35

expression ($n=16$, 12.0 ± 23.82 months, $p < 0.001$). **b** The median overall survival of GBM patients with high LPTM4B-35 expression ($n=23$) was 12.5 ± 8.34 months, again significantly shorter than that of patients with low LPTM4B-35 expression ($n=16$, 29.6 ± 23.7 months, $p < 0.001$)